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Background: Tramalol overdose is disproportionately more common in Iran. In recent years, Tramadol overdose
has become one of the most common causes of poisoning admissions to emergency departments in this country.
To the best of our knowledge, there is little or no information regarding the toxicokinetic properties of Tramadol
such as its half life. Given the fact that poisoning management should be based on the toxicokinetic of substances,
we aimed at investigating the half life of Tramadol in man as a critical toxicokinetic variable in overdose.
Methods: Blood samples of each patient were collected on admission and repeated later. Plasma was harvested
after separation from blood cells by centrifugation and quantified using HPLC method. Calculations were performed
on Tramadol blood concentration quantities.
Findings: Demographic: Most of cases were men (81.81%). Mean (Standard Deviation (SD), min-max) age was 23
(8.142, 17-40). Serum Tramadol levels: Mean (SD, min-max) first Tramadol concentration was 786.91 (394.53, 391-1495).
Mean (SD, min-max) second Tramadol concentration was 433.09 (269.63, 148-950). Mean (SD, min-max) of Tramadol
half life was calculated as 9.24 hour (2.310, 4.99-13.45) Associations: Half life was associated with higher concentrations
(r=0.708 Sig=0.015).
Conclusion: We report the mean half life of tramadol in overdose to be 9.24 hours which is remarkably higher than
that measured in previous pharmacokinetic studies. We also concluded that Tramadol half life is dose dependent in
overdose which may explain the further consequences of severe overdoses.
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Background
Tramadol is a synthetic, centrally acting analgesic opioid.
It is mainly metabolized to O-desmethyl Tramadol (M1),
which is also active [1]. Tramadol has been approved in
some countries since 1980 and become the most fre-
quently prescribed opioid around the globe [2]. Tramadol
is rapidly and almost fully absorbed after single or mul-
tiple oral administrations. Nevertheless, the mean absolute
bioavailability of Tramadol is reported to be 65–70%
which is due to its extensive first-pass hepatic metabolism
[3]. The bioavailability rises to >90% with multiple doses.
The large volume of distribution (306 liters) after oral ad-
ministration suggests its high tissue affinity [4]. Although
frequently prescribed, few data on kinetic of Tramadol in
humans are available. In a study performed on horses, half-* Correspondence: AfshariR@mums.ac.ir
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unless otherwise stated.life after intravenous and intramuscular administration was
82 ± 10 and 92 ± 14 min, respectively [5]. In the rat, the ter-
minal elimination half-life of Tramadol is approximately
3 hours [6]. The distribution and elimination half-lives in
humans were 1.02 and 141.9 min respectively [7].
Medicinal toxicities are common in Iran [8]. In recent
years, Tramadol overdose has become one of the most
common causes of poisoning admissions to emergency
departments in this country [9,10]. The increasing number
of Tramadol abuse and overdoses provokes the need for a
more profound knowledge about the kinetic/dynamic pro-
file of Tramadol in overdose. Several studies have been
performed to measure the pharmacokinetic profile of this
drug [11]. However, to the best of our knowledge, there is
little information regarding the toxicokinetic properties of
Tramadol such as its half life.
We previously reported the clinical manifestations of
Tramadol overdose in relation to alleged dose [12]. The
unique feature of this study is defining the half life oftral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Calculated Tramadol Half-life in relation to first
measured blood concentration of Tramadol in overdose
patients. Half life is associated with higher concentrations
(r = 0.708 Sig = 0.015).
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Method
This prospective cross-sectional study was performed in
Imam Reza University Hospital Poison Center, (Mashhad,
Iran) [13] from July 2012 to September 2012. Totally,
25 patients who were admitted to the hospital with
Tramadol overdose and were confirmed to have
ingested more than the recommended therapeutic dose
(primarily by urinary test and secondarily by blood
test) met the entry requirement. Among them, 11 pa-
tients consented to give at least two blood samples. Ex-
clusion criteria were met and the treatment of patients
[14,15] was not influenced by the process of data col-
lecting. Ethics approval was obtained from ethics com-
mittee of the Mashhad University of Medical Sciences
(MUMS/89/1876).
Blood samples, collected in heparinised glass tubes
on admission and repeated later were investigated for
Tramadol serum concentration using a high-performance
liquid chromatographic system (HPLC) (Knauer, Germany)
with the method explained in [16]. Intra- and interday
variabilities were measured to determine the precision
of the HPLC method. The relative standard deviation
(RSD) of intraday and interday variations for Tramadol
was 1.7% and 1.4% respectively, indicating that the
method was repeatable. To measure the Half Life of
Tramadol, first order kinetic (Formula: Nt = N0(1/2)
t/t1/2)
was assumed. Calculations were performed on blood con-
centration quantities. N0 denotes the first quantity, Nt is
the quantity that is remained at the time of t and t1/2
denotes half-life.
All calculations were performed manually with the
help of Microsoft® Office Excel 2003 and SPSS version
13.0 (SPSS Inc., Chicago, IL, USA).
Findings
Most of patients (9) were men (81.81%). Mean (Standard
Deviation (SD), min-max) age was 23 years (8.142, 17–40).
Mean (SD, min-max) first Tramadol concentration was
786.91 mg/dL (394.53, 391–1495). Mean (SD, min-max)
second Tramadol concentration was 433.09 mg/dL (269.63,
148–950). Mean time interval from 1st to 2nd blood sam-
pling was 8.23 hours (1.421, 5.5-11). Mean (SD, min-max)
of Tramadol half life was calculated as 9.24 hours (2.310,
4.99-13.45). Half life was associated with higher concentra-
tions (r = 0.708 Sig = 0.015) (Figure 1).
Discussion
In this study, we found the half life of Tramadol to be
9.24 ± 2.310 hours in man in overdose which is compar-
able to that reported by Ardakani et al. [17]. They dem-
onstrated the half life of Tramadol in healthy humans tobe approximately 7 hours. Importantly, we demonstrated
that Tramadol half life is dose dependent in overdose
which may explain the further consequences of severe
overdoses.
Tramadol is mostly metabolised by O- and N-de-
methylation and conjugation reactions which result in
glucuronides and sulphates [18]. The wide variability
in the pharmacokinetic properties of Tramadol is
partly due to cytochrome P450 (CYP) polymorphism.
In fact, Tramadol is mostly metabolized by the highly
polymorphic enzyme CYP 2D6, meaning patients with
different CYP2D6 genotypes may experience different
degrees of pain relief and side effects [19,20]. To
obtain more accurate results, we suggest that the toxi-
cokinetic of Tramadol and its metabolites be studied
in specific phenotypes. We also believe that in order
to determine the definitive toxicokinetic profile of
Tramadol, further investigations should be performed
on larger groups.
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